Dimetridazole Premix Veterinary Grade API is supplied as a crystalline active pharmaceutical ingredient designated by the product code DMT-PREMIX-200-API. The chemical identity is 1,2-dimethyl-5-nitroimidazole, with CAS registry number 551-92-8, molecular formula C₅H₇N₃O₂, and relative molecular mass 141.13 g mol⁻¹. The product is packaged in 25 kg net weight fibre drums with double low-density polyethylene liners and is controlled at release through a batch-specific certificate of analysis. Storage is specified at 20–25 °C in tight containers protected from light. The solid state is a white to pale yellow crystalline powder with a melting range of 138.0–141.0 °C. Aqueous solubility is limited; the compound dissolves in dilute mineral acids and in organic solvents, which has direct consequences for solution, injection, and premix formulation. The material is intended for further processing into tablets, capsules, powders, granules, premixes, and solutions under current good manufacturing practice. Regulatory status is not uniform across jurisdictions. Within the European Union, dimetridazole is listed as a prohibited substance for food-producing animals in Commission Regulation (EU) No 37/2010, Table 2; downstream uses are therefore restricted to non-food-producing species or jurisdictions where specific authorization exists.

Which Release Specifications Apply to Dimetridazole Premix Veterinary Grade API?

Release testing follows a compendial-style monograph pattern because no harmonized pharmacopoeial monograph for dimetridazole is available in all regions. The certificate of analysis therefore combines identity, purity, residual solvent, and particle size controls relevant to veterinary dosage-form manufacture. The chromatographic assay uses an externally validated high-performance liquid chromatographic method with a C18 stationary phase and ultraviolet detection. System suitability requirements include resolution between dimetridazole and the main related substance, a tailing factor not exceeding 2.0 for the main peak, and repeatability of injection with relative standard deviation ≤1.0% across 5 replicate injections. The acceptance criteria are summarized in the following release matrix.

These limits are applied to every batch before release. In addition, the API is tested for clarity in acidic solution because insoluble particles can block sterilizing filters during injection manufacturing. The particle size specification is adjusted to the intended downstream process; a finer grade with D90 ≤50 µm is available for suspensions and low-dose dry blends, while a coarser grade with D90 ≤150 µm is used for granulation routes to minimize dust and electrostatic charging.

High-Shear Granulation and Direct Compression Boundaries for Tablet and Capsule Manufacture

For tablet and capsule manufacture, high-shear granulation is the preferred route when the active pharmaceutical ingredient is to be compressed at drug loads above 30% w/w. A production-scale process is developed in a high-shear granulator with bottom-driven impeller and side chopper. Impeller tip speed is maintained between 2 m/s and 5 m/s, and granulation time after binder addition is limited to 2–4 min to avoid overgranulation. Aqueous binder systems based on povidone or pregelatinized starch at 2–5% w/w solids are added while the powder bed is agitated. The wet mass is milled through a 1.2 mm screen and dried in a fluid-bed dryer at inlet air temperature 55–65 °C until the granulate moisture content is ≤2.0%. Dry granulate is then passed through an oscillating granulator fitted with a 0.8 mm screen and blended with extragranular disintegrant, glidant, and lubricant. Tablet compression is performed on a rotary tablet press; for a 10 mm flat-faced beveled tablet, hardness is adjusted to 60–90 N, and friability is controlled at ≤1.0% using USP 1216.

Direct compression is restricted to low-dose or prototype formulations because the milled active ingredient exhibits cohesive flow and electrostatic adhesion to stainless steel contact surfaces. Direct-compression blends typically contain 40–60% w/w spray-dried lactose, 20–30% w/w microcrystalline cellulose, 0.5–1.0% w/w colloidal silicon dioxide, and 0.5–1.5% w/w magnesium stearate. The blend is compressed on a high-speed rotary press at turret speeds of 25–50 rpm. Capsule filling is carried out on an automatic capsule machine with powder dosing units; the machine settings are adjusted to achieve weight variation consistent with USP 905, with individual capsule weight within ±5% of the mean. Dissolution evaluation for immediate-release tablets is performed in 900 mL of 0.1 mol/L hydrochloric acid at 37 ± 0.5 °C using USP 711 apparatus 2 at 50 rpm. The Q value and sampling time are formulation-dependent; published data for this specific configuration is limited.

Dry powder and granule processing for oral sachets or measuring scoops requires control of the fine-particle fraction because the sub-10 µm content drives dust formation and content non-uniformity. Particle size specification often includes a D10 control point in addition to D50 and D90; a D10 below 20 µm may be appropriate for immediate dispersion in water, but values below 5 µm can create weighing and filling variability on auger-type powder fillers. Granulation by roller compaction or fluid-bed top-spray reduces dust and improves flow. A fluid-bed top-spray process using an aqueous binder at 5–10% w/w of the dry charge is operated at product temperature 30–40 °C and spray rate 5–10 g/min/kg of API-carrier blend, with final moisture ≤3.0%. These process windows are established on production-scale equipment because laboratory-scale granulators do not reproduce the same droplet size distribution and drying capacity.

Injectable solution preparation requires pH adjustment because the neutral molecule has limited solubility. Protonation in acidic media increases solubility; formulation development evaluates hydrochloric acid or citrate buffer systems in the pH range 2.5–3.5, with the final pH confirmed by solubility screening. Compounding is performed in a glass-lined vessel under nitrogen sparging; nitroimidazoles are light-sensitive and may react with trace metal ions. Terminal sterilization is achieved by autoclaving at 121 °C for 15 min or by membrane filtration through 0.22 µm sterilizing-grade polyvinylidene fluoride membranes. Membrane adsorption is checked during filter validation because low-concentration solutions can lose active ingredient to polymeric membranes. The solution is filled into amber Type I glass vials and sealed with chlorobutyl rubber stoppers under inert headspace. Stability protocols include pH, appearance, assay, and sub-visible particle testing according to USP 787 and USP 788. Contact surfaces are selected from 316L stainless steel, borosilicate glass, and polytetrafluoroethylene-lined seals; strong reducing agents and uncoated rubber closures are incompatible.

Because dimetridazole is a weak base with limited aqueous solubility, oral solution development follows a similar pH-dependent solubility rationale. An aqueous vehicle adjusted to acidic pH with hydrochloric acid or citric acid is used to dissolve the active ingredient; sodium metabisulfite or edetate disodium may be included as stabilizers, but their compatibility must be confirmed because nitroimidazoles are sensitive to reducing and oxidizing agents. Oral solutions are packaged in amber polyethylene terephthalate or Type III glass containers with child-resistant closures. Dissolved oxygen is reduced by nitrogen purging during compounding, and the filling line is operated under low-intensity light. Microbial quality is controlled according to USP 1111; oral liquids for veterinary use are commonly preserved with methyl paraben and propyl paraben at combined concentrations not exceeding 0.2% w/v, although preservative efficacy testing according to USP 51 determines the final level. Published data for this specific configuration is limited; the formulation must be validated for the intended species and dose volume.

When Low-Dose Premix Homogeneity Dictates Carrier Selection for Non-Food Species

Premix and granule manufacture requires geometric dilution because the active ingredient may be incorporated at low final concentrations. The API is first triturated with a carrier such as calcium carbonate, lactose monohydrate, or wheat middlings. Carrier selection is based on bulk density, particle size distribution, oil absorption capacity, and electrostatic charging. A carrier fraction with particle size between 150 µm and 500 µm normally reduces segregation during pneumatic conveying. Production-scale blending is conducted in a ribbon mixer or double-cone blender at 50–65% vessel fill; mixing time is established by blend uniformity sampling at 10 locations using a unit-dose sampling thief. The acceptance criterion for the active ingredient in a low-dose premix is typically 90–110% of the declared concentration with a relative standard deviation of ≤5.0%. Granules are produced by wet granulation with 5–15% w/w aqueous binder, dried to moisture ≤3.0%, and packaged in foil-lined bags. Vacuum transfer and closed discharge systems are used to control dust because the compound is a suspected mutagen and occupational exposure should be minimized according to local limits.

Metronidazole and ronidazole are the nearest structural comparators; dimetridazole differs primarily in the N1 substituent and the resulting polarity and metabolism. Dimetridazole carries a methyl group at N1 and a methyl group at C2, whereas metronidazole carries a 2-hydroxyethyl group at N1. The absence of the hydroxyethyl group reduces aqueous solubility relative to metronidazole and alters partition behaviour in biological membranes. Ronidazole also carries a methyl group at N1 but has a different C2 side chain, which changes metabolic lability and residue depletion. These structural differences are not interchangeable in formulation: metronidazole can be processed more readily into high-concentration aqueous solutions, while dimetridazole often requires organic co-solvents or low-pH adjustment. Dimetridazole also tends to generate more dust during dry processing than metronidazole because of its crystal habit and milling characteristics; wet granulation or vacuum containment is therefore introduced earlier in development. The following table summarizes the structural and formulation-relevant differences.